Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
25 1월 2023 - 11:00PM
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and
TSX-V: ACST), a late-stage, specialty pharma company advancing
three clinical stage drug candidates addressing rare and orphan
diseases, announces that it has received notification from the
NASDAQ Listing Qualifications Department ("NASDAQ") that it is
eligible for an additional 180 calendar days, or until July 24,
2023, to regain compliance with the minimum $1.00 per share
requirement for continued listing.
On July 27, 2022, Acasti received notification
from NASDAQ for not maintaining a minimum bid price of US$1.00 per
share for 30 consecutive business days (the “Minimum Bid Price
Rule”). The Company was given 180 calendar days, or until January
23, 2023, to regain compliance.
On January 24, 2023, Acasti received
notification from NASDAQ that it is eligible for an additional 180
calendar days, or until July 24, 2023, to regain compliance with
the Minimum Bid Price Rule. Acasti was granted the second extension
because it meets the continued listing requirements for the market
value of publicly held shares and all other initial listing
standards for NASDAQ Capital Market, except for the bid price
requirement. To regain compliance, Acasti's shares must close at
US$1.00 per share or more for a minimum of 10 consecutive business
days prior to July 24, 2023. Acasti will continue to monitor the
bid price for its common shares and consider various available
options if Acasti’s common shares do not trade at a level that is
likely to regain compliance with the Minimum Bid Price Rule.
About Acasti
Acasti is a late-stage specialty pharma company
with drug delivery technologies and drug candidates addressing rare
and orphan diseases. Acasti’s novel drug delivery technologies have
the potential to improve the performance of currently marketed
drugs by achieving faster onset of action, enhanced efficacy,
reduced side effects, and more convenient drug delivery—all which
could help to increase treatment compliance and improve patient
outcomes. Acasti’s three lead clinical assets have each been
granted Orphan Drug Designation by the FDA, which provide the
assets with seven years of marketing exclusivity post-launch in the
United States, and additional intellectual property protection with
over 40 granted and pending patents. Acasti’s lead clinical assets
target underserved orphan diseases: (i) GTX-104, an intravenous
infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life
threatening medical emergency in which bleeding occurs over the
surface of the brain in the subarachnoid space between the brain
and skull; (ii) GTX-102, an oral mucosal spray targeting
Ataxia-telangiectasia (A-T), a progressive, neurodegenerative
genetic disease that primarily affects children, causing severe
disability, and for which no treatment currently exists; and (iii)
GTX-101, a topical spray targeting Postherpetic Neuralgia (PHN), a
persistent and often debilitating neuropathic pain caused by nerve
damage from the varicella zoster virus (shingles), which may
persist for months and even years.
For more information, please visit:
https://www.acasti.com/en.
Forward-Looking Statements
Statements in this press release that are not
statements of historical or current fact constitute
“forward-looking information” within the meaning of Canadian
securities laws and “forward-looking statements” within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995, as
amended, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended
(collectively, “forward looking statements”). Such forward looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of Acasti
to be materially different from historical results or from any
future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements containing the terms “believes,” “belief,” “expects,”
“intends,” “anticipates,” “potential,” “should,” “may,” “will,”
“plans,” “continue”, “targeted” or other similar expressions to be
uncertain and forward looking. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The forward-looking
statements in this press release are based upon Acasti’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties. All forward-looking statements contained in this
press release speak only as of the date on which they were made.
Acasti undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by applicable
securities laws. Neither NASDAQ, the TSXV nor its Regulation
Services Provider (as that term is defined in the policies of the
TSXV) accepts responsibility for the adequacy or accuracy of this
release.
Acasti Contact:
Jan D’AlviseChief Executive OfficerTel:
450-686-4555Email:info@acasti.com www.acasti.com
Investor Relations:Robert BlumLytham Partners,
LLC602-889-9700ACST@lythampartners.com
Acasti Pharma (TSXV:ACST)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Acasti Pharma (TSXV:ACST)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024